BIOGEN INC
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 14, 2024
BIIB$254.87+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled “Executive Compensation Tables,”"Compensation Discussion and Analysis" and“Corporate Governance” contained in the proxy statement for our 2024 annual meeting of stockholders.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.